Gs. Friedrichs et al., ANTIFIBRILLATORY EFFICACY OF LONG-TERM TEDISAMIL ADMINISTRATION IN A POSTINFARCTED CANINE MODEL OF ISCHEMIC VENTRICULAR-FIBRILLATION, Journal of cardiovascular pharmacology, 31(1), 1998, pp. 56-66
The electrophysiologic and antifibrillatory properties of tedisamil (K
C-8857) were studied in vivo in a conscious canine model of sudden car
diac death. Male mongrel dogs were anesthetized, and surgical anterior
myocardial infarction was induced by a 2-h occlusion, with reperfusio
n of the left anterior descending coronary artery. Three to five days
after infarction, dogs were subjected to programmed electrical stimula
tion (PES) to identify those at risk for ischemia-induced ventricular
fibrillation. Previous studies documented that dogs with a significant
anterior-wall infarction develop ventricular tachycardia in response
to PES and are at an increased risk for sudden cardiac death on imposi
tion of a transient ischemic event in a region remote from the infarct
-related artery. PES-inducible animals were randomized to either oral
placebo or oral tedisamil treatment (3 mg/kg, b,i,d for 4 days, Group
1, n = 8). Control animals received empty gelatin capsules (Group 2, n
= 8). The effective refractory period and QTc interval were unchanged
after 3 days of oral placebo or tedisamil dosing. Arrhythmic activity
after drug administration was not observed In dogs treated with tedis
amil, PES induction of ventricular tachycardia was reduced significant
ly in the tedisamil-treated group (100% inducible before drug vs. 9% i
nducible after drug; p < 0.05), In the sudden-cardiac-death protocol,
tedisamil reduced the incidence of lethal ischemic arrhythmias develop
ing in response to acute posterolateral myocardial ischemia. Tedisamil
-treated animals exhibited a 100% compared with a 25% survival rate in
the control group (p < 0.05). Anterior-wall infarct size, expressed a
s a percentage of the left ventricle, did not differ between groups: G
roup 1 = 20 +/- 1%; Group 2 = 22 +/- 1%. Our findings suggest that ted
isamil might be useful in the prevention of malignant ventricular arrh
ythmias in myocardial ischemic injury.